A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)
This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.
Melanoma
BIOLOGICAL: Pegylated Interferon Alfa-2b|BIOLOGICAL: Pegylated Interferon Alfa-2b
Percentage of Participants Experiencing Adverse Events (AEs), An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment., From first dose through follow-up; up to 13 months|Percentage of Participants Discontinuing Study Drug Because of AEs, An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment., From first dose to last dose of treatment; up to 12 months
This study will assess the safety of Pegylated Interferon Alfa-2b (PEG-IFN) as an adjuvant treatment for melanoma.